Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis

Abstract

Background and Aims The availability of biological agents for inflammatory bowel disease has increased over the past years. In this systematic review and meta‐analysis, we aimed to explore time trends in clinical response and clinical remission rates in Crohn's disease (CD) patients treated with biologics while discussing the need for new strategies. Methods MEDLINE, Cochrane, and ISI Web of Science databases were searched for randomized placebo‐controlled trials with biological agents in moderate‐to‐severe CD patients. Sub‐group and meta‐regression analyses compared treatment and placebo by calculating the pooled odds ratios of clinical remission and clinical response, across time categories and publication year. We also estimated the proportion of patients achieving clinical remission and clinical response by comparing both groups according to the publication year. Results Twenty‐five trials were included in the systematic review, which enrolled 8879 patients between 1997 and 2022. The clinical remission and clinical response odds, in induction and maintenance, have been constant over time, as no statistically significant differences were found between time categories (interaction p‐values: clinical remission [induction, p = 0.19; maintenance, p = 0.24]; clinical response [induction, p = 0.43; maintenance, p = 0.59]). In meta‐regression analyses, publication year did not influence these outcomes (clinical remission [induction, OR 1.01{95% CI 0.97–1.05}, p = 0.72; clinical response [induction, OR 1.01{95% CI 0.97–1.04]; p = 0.63; maintenance, OR 1.03{95% CI 0.98–1.07}; p = 0.21]), with the exception of clinical remission in maintenance studies, which presented a decreased effect (odds ratio 0.97{95% CI 0.94–1.00}, p = 0.03]). Conclusions Our review highlights that the odds of clinical outcomes in CD patients receiving biological treatment relative to placebo have been stable in the last decades.

UEG Journal's impact and vision for the future

“…For example, two visual abstracts on IBD manuscripts have garnered more than 13,000 views. 8,9 This is a great engagement not only amplified the reach of our content, but also provided an invaluable platform for knowledge exchange and collective learning.…”

Mycobacterium avium ssp. paratuberculosis and Crohn’s Disease—Diagnostic Microbiological Investigations Can Inform New Therapeutic Approaches

“…However, there is growing global research interest in the role of MAP in association with human and animal diseases [5]. The decision to assign MAP to MAC should be reconsidered given the zoonotic potential of the organism and the dwindling availability of diagnostic tests and therapeutics for CD [6][7][8][9].…”

Hot Topics on Nutrition in IBD

“…Most biologics have only achieved a clinical remission rate of approximately 40% at 52 weeks [74]. Several strategies have been proposed to surpass the therapeutic ceiling in the future, including the combination of biologics/small molecules, the integration of drugs and nutrition, and the modulation of gut microbiota [75]. Using diet as an adjuvant therapy is an attractive strategy relying on accessibility and lack of associated complications [71].…”